Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial

最大值 药代动力学 医学 药效学 生物等效性 德诺苏马布 免疫原性 药理学 临床终点 不利影响 置信区间 随机对照试验 内科学 免疫学 抗体 骨质疏松症
作者
Yinhan Guo,Tingting Guo,Yujing Di,Wenyu Xu,Zhitian Hu,Yanfeng Xiao,Heze Yu,Jie Hou
出处
期刊:Expert Opinion on Biological Therapy [Taylor & Francis]
卷期号:23 (8): 705-715 被引量:5
标识
DOI:10.1080/14712598.2023.2178298
摘要

Background MW031 is a biosimilar candidate of denosumab (Prolia®). This study aimed to compare the pharmacokinetics, pharmacodynamics, safety and immunogenicity of MW031 to denosumab in healthy Chinese participants.Research design and methods In this single-center, randomized, double-blind, parallel-controlled, single-dose trial, participants were given 60 mg MW031 (N = 58) or denosumab (N = 61) by subcutaneous injection and observed for 140 days. The primary endpoint was the bioequivalence of PK parameters (Cmax, AUC0-∞), and secondary endpoints including PD parameter, safety, and immunogenicity.Results A comparison of main PK parameters showed that the geometric mean ratios (GMR) (90% confidence intervals [CIs]) of AUC0-∞ and Cmax for MW031 over denosumab were 105.48% (98.96%, 112.43%) and 98.58% (92.78%, 104.75%), respectively. The inter-CV values of AUC0-∞ and Cmax for MW031 ranged from 19.9% to 23.1%. PD parameter (sCTX) in the MW031 and denosumab groups were similar, and the positivity rates of immunogenicity were 0% in both groups. This study also showed similar safety profiles in both groups, and there were no drug-related, high-incidence and previously unreported adverse reactions.Conclusion This trial confirmed similar pharmacokinetic profiles of MW031 and denosumab in healthy male participants, and pharmacodynamic profile, immunogenicity and safety were comparable for both drugs.Trial registration NCT04798313; CTR20201149
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
2秒前
搜集达人应助ZY采纳,获得10
2秒前
2秒前
许许完成签到,获得积分10
3秒前
来可追发布了新的文献求助10
4秒前
坡区小旋风完成签到,获得积分10
4秒前
orixero应助早123采纳,获得10
4秒前
光崽是谁发布了新的文献求助10
4秒前
4秒前
JamesPei应助wzj采纳,获得10
5秒前
hua发布了新的文献求助10
5秒前
RL发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
7秒前
7秒前
zxcvvbnm完成签到 ,获得积分10
7秒前
野原x之助发布了新的文献求助10
8秒前
adeno发布了新的文献求助10
8秒前
9秒前
kyJYbs发布了新的文献求助10
9秒前
赘婿应助mdmdd采纳,获得10
10秒前
10秒前
js110完成签到,获得积分20
10秒前
10秒前
光崽是谁完成签到,获得积分10
11秒前
YJL发布了新的文献求助200
11秒前
zzzyyyppp发布了新的文献求助10
12秒前
量子星尘发布了新的文献求助150
12秒前
JamesPei应助木瓜木瓜采纳,获得10
13秒前
柳月萍发布了新的文献求助10
13秒前
xxxxc完成签到,获得积分10
13秒前
Velvet完成签到,获得积分10
14秒前
张恒发布了新的文献求助10
14秒前
完美世界应助活力的兔子采纳,获得10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
International Encyclopedia of Business Management 1000
Encyclopedia of Materials: Plastics and Polymers 1000
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Hidden Generalizations Phonological Opacity in Optimality Theory 1000
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4933690
求助须知:如何正确求助?哪些是违规求助? 4201746
关于积分的说明 13054958
捐赠科研通 3975817
什么是DOI,文献DOI怎么找? 2178602
邀请新用户注册赠送积分活动 1194932
关于科研通互助平台的介绍 1106316